Nolte Marc W, Löscher Wolfgang, Herden Christiane, Freed William J, Gernert Manuela
Department of Pharmacology, Neuroscience Discovery Research, Abbott GmbH & Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany.
Neurobiol Dis. 2008 Sep;31(3):342-54. doi: 10.1016/j.nbd.2008.05.010. Epub 2008 Jul 15.
Neural transplantation has been investigated experimentally and clinically for the purpose of developing new treatment options for intractable epilepsy. In the present study we assessed the anticonvulsant efficacy and safety of bilateral allotransplantation of genetically engineered striatal GABAergic rat cell lines into the substantia nigra pars reticulata (SNr). Rats with previously-established seizures, induced by amygdala kindling, were used as a model of temporal lobe epilepsy. Three cell lines were transplanted: (1) immortalized GABAergic cells (M213-2O) derived from embryonic rat striatum; (2) M213-2O cells (CL4) transfected with human GAD67 cDNA to obtain higher GABA synthesis than the parent cell line; and (3) control cells (121-1I), also derived from embryonic rat striatum, but which did not show GAD expression. A second control group received injections of medium alone. Transplantation of M213-2O cells into the SNr of kindled rats resulted in significant but transient anticonvulsant effects. Neither control cells nor medium induced anticonvulsant effects. Strong tissue reactions were, however, induced in the host brain of kindled but not of non-kindled rats, and only in animals that received grafts of genetically modified CL4 cells. These tissue reactions included graft rejection, massive infiltration of inflammatory immune cells, and gliosis. The anticonvulsant effect of M213-2O cells emphasizes the feasibility of local manipulations of seizures by intranigral transplantation of GABA-producing cells. On the other hand, the present data suggest that kindling-induced activation of microglia in the SNr can enhance immune reactions to transplanted cells. In this case, under conditions of further immunological stimulation by CL4 cells, transfected with a human cDNA, substantial immune reactions occurred. Thus, it appears that the condition of the host brain and the production of foreign proteins by transplanted cells have to be considered in estimating the risks of rejection of transplants into the brain.
为了开发难治性癫痫的新治疗方案,已经对神经移植进行了实验和临床研究。在本研究中,我们评估了将基因工程化的纹状体GABA能大鼠细胞系双侧同种异体移植到黑质网状部(SNr)的抗惊厥疗效和安全性。将先前由杏仁核点燃诱导癫痫发作的大鼠用作颞叶癫痫模型。移植了三种细胞系:(1)源自胚胎大鼠纹状体的永生化GABA能细胞(M213 - 2O);(2)用人类GAD67 cDNA转染的M213 - 2O细胞(CL4),以获得比亲代细胞系更高的GABA合成;(3)对照细胞(121 - 1I),也源自胚胎大鼠纹状体,但不显示GAD表达。第二个对照组仅接受培养基注射。将M213 - 2O细胞移植到点燃大鼠的SNr中产生了显著但短暂的抗惊厥作用。对照细胞和培养基均未诱导抗惊厥作用。然而,仅在接受转基因CL4细胞移植的点燃大鼠而非未点燃大鼠的宿主脑中诱导了强烈的组织反应。这些组织反应包括移植排斥、炎性免疫细胞的大量浸润和胶质增生。M213 - 2O细胞的抗惊厥作用强调了通过向黑质内移植产生GABA的细胞进行局部控制癫痫发作的可行性。另一方面,目前的数据表明,点燃诱导的SNr中微胶质细胞的激活可增强对移植细胞的免疫反应。在这种情况下,在用人类cDNA转染的CL4细胞进行进一步免疫刺激的条件下,发生了大量免疫反应。因此,在评估脑内移植排斥风险时,似乎必须考虑宿主脑的状况和移植细胞产生的外源蛋白。